A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors

Summary

This research study is evaluating the drug Ramucirumab as a possible treatment for Advanced, Progressive Carcinoid Tumors.

Timeline

Start

2016-06-14

Primary completion

2022-12-31

Completion

2023-12-31

Publications

• Perez K, Kulke MH, Zheng H, Allen J, Clark J, Enzinger AC, Enzinger PC, Johnson BE, McCleary NJ, Parikh A, Patel A, Rubinson D, Yurgelun MB, Ramsey K, Johnson E, Graham C, Chan JA. A phase II study of ramucirumab and somatostatin analog therapy in patients with advanced neuroendocrine tumors. Oncologist. 2025 Jan 17;30(1):oyae364. doi: 10.1093/oncolo/oyae364.

Drugs

Indications